FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Roger Jelliffe

Research Profile

Concepts & Ideas

Chemicals & Drugs

Physiology

Pharmacokinetics

Procedures

Activities & Behaviors

Disorders

Cystic Fibrosis

Co-author Network

Publications

TOP 3
Parish P Sedghizadeh; Roger W Jelliffe; Allan C Jones; Andrew Kiss; Chris LaVallee; Anh D Le; Peter Lee; Michael Neely
Population pharmacokinetic and pharmacodynamic modeling for assessing risk of bisphosphonate-related osteonecrosis of the jaw.
Roger W Jelliffe
Some comments and suggestions concerning population pharmacokinetic modeling, especially of digoxin, and its relation to clinical therapy.
Michael N Neely; Alan Schumitzky; Michael G van Guilder; Walter M Yamada; Roger W Jelliffe
Accurate detection of outliers and subpopulations with Pmetrics, a nonparametric and parametric pharmacometric modeling and simulation package for R.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Roger Jelliffe (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Parish P Sedghizadeh; Roger W Jelliffe; Allan C Jones; Andrew Kiss; Chris LaVallee; Anh D Le; Peter Lee; Michael Neely
Population pharmacokinetic and pharmacodynamic modeling for assessing risk of bisphosphonate-related osteonecrosis of the jaw.
Oral surgery, oral medicine, oral pathology and oral radiology 2013;115(2):224-32.
2012: Roger W Jelliffe
Some comments and suggestions concerning population pharmacokinetic modeling, especially of digoxin, and its relation to clinical therapy.
Therapeutic drug monitoring 2012;34(4):368-77.
2012: Michael N Neely; Alan Schumitzky; Michael G van Guilder; Walter M Yamada; Roger W Jelliffe
Accurate detection of outliers and subpopulations with Pmetrics, a nonparametric and parametric pharmacometric modeling and simulation package for R.
Therapeutic drug monitoring 2012;34(4):467-76.
2008: Andrea L H Kwa; Juraj Sprung; Michael Van Guilder; Roger W Jelliffe
A population pharmacokinetic model of epidural lidocaine in geriatric patients: effects of low-dose dopamine.
Therapeutic drug monitoring 2008;30(3):379-89.
2008: Iona Macdonald; Christine E Staatz; Roger W Jelliffe; Alison H Thomson
Evaluation and comparison of simple multiple model, richer data multiple model, and sequential interacting multiple model (IMM) Bayesian analyses of gentamicin and vancomycin data collected from patients undergoing cardiothoracic surgery.
Therapeutic drug monitoring 2008;30(1):67-74.
2006: William C Shoemaker; Charles C J Wo; Kevin Lu; Li-Chien Chien; Peter Rhee; David S Bayard; Demetrios Demetriades; Roger W Jelliffe
Noninvasive hemodynamic monitoring for combat casualties.
Military medicine 2006;171(9):813-20.
2006: William C Shoemaker; David S Bayard; Charles C J Wo; Andreas Botnen; Linda S Chan; Li-Chien Chien; Kevin Lu; Demetrios Demetriades; Howard Belzberg; Roger W Jelliffe
Stochastic model for outcome prediction in acute illness.
Computers in biology and medicine 2006;36(6):585-600.
2006: Aida Bustad; Dimiter Terziivanov; Robert Leary; Ruediger Port; Alan Schumitzky; Roger W Jelliffe
Parametric and nonparametric population methods: their comparative performance in analysing a clinical dataset and two Monte Carlo simulation studies.
Clinical pharmacokinetics 2006;45(4):365-83.
2006: William C Shoemaker; Charles C J Wo; Kevin Lu; Li-Chien Chien; David S Bayard; Howard Belzberg; Demetrios Demetriades; Roger W Jelliffe
Outcome prediction by a mathematical model based on noninvasive hemodynamic monitoring.
The Journal of trauma 2006;60(1):82-90.
2005: William C Shoemaker; David S Bayard; Charles C J Wo; Linda S Chan; Li-Chien Chien; Kevin Lu; Roger W Jelliffe
Outcome prediction in chest injury by a mathematical search and display program.
Chest 2005;128(4):2739-48.
2005: William C Shoemaker; David S Bayard; Andreas Botnen; Charles C J Wo; Ashutosh Gandhi; Li-Chien Chien; Kevin Lu; Matthew J Martin; Linda S Chan; Demetrios Demetriades; Nasrollah Ahmadpour; Roger W Jelliffe
Mathematical program for outcome prediction and therapeutic support for trauma beginning within 1 hr of admission: a preliminary report.
Critical care medicine 2005;33(7):1499-506.
2005: William C Shoemaker; David S Bayard; Charles C J Wo; Andreas Botnen; Nasarolla Ahmedpour; Ashutosth Gandhi; Demetrios Demetriades; Roger W Jelliffe
A stochastic control program to predict outcome and to support therapeutic decisions: a preliminary report.
Journal of clinical monitoring and computing 2005;19(3):223-30.
2004: David S Bayard; Roger W Jelliffe
A Bayesian approach to tracking patients having changing pharmacokinetic parameters.
Journal of pharmacokinetics and pharmacodynamics 2004;31(1):75-107.
2004: Ruediger E Port; Daniela Kiepe; Michael Van Guilder; Roger W Jelliffe; Otto Mehls
Recombinant human erythropoietin for the treatment of renal anaemia in children: no justification for bodyweight-adjusted dosage.
Clinical pharmacokinetics 2004;43(1):57-70.
2003: Patrice Martin; Nathalie Bleyzac; Gérard Souillet; Claire Galambrun; Yves Bertrand; Pascal Maire; Roger W Jelliffe; Gilles Aulagner
Clinical and pharmacological risk factors for acute graft-versus-host disease after paediatric bone marrow transplantation from matched-sibling or unrelated donors.
Bone marrow transplantation 2003;32(9):881-7.
2003: Patrice Martin; Nathalie Bleyzac; Gérard Souillet; Claire Galambrun; Yves Bertrand; Pascal Maire; Roger W Jelliffe; Gilles Aulagner
Relationship between CsA trough blood concentration and severity of acute graft-versus-host disease after paediatric stem cell transplantation from matched-sibling or unrelated donors.
Bone marrow transplantation 2003;32(8):777-84.
2003: Florent Rougier; stephane corvaisier; michel ducher; Daniel Claude; Roger W Jelliffe; Pascal Maire
[PK/PD modeling of aminoglycoside nephrotoxicity].
Pathologie-biologie 2003;51(4):234-6.
2003: Florent Rougier; Daniel Claude; Michel Maurin; Alexandre Sedoglavic; michel ducher; stephane corvaisier; Roger W Jelliffe; Pascal Maire
Aminoglycoside nephrotoxicity: modeling, simulation, and control.
Antimicrobial agents and chemotherapy 2003;47(3):1010-6.
2003: Alexander Vinks; Jan G Den Hollander; Shelley E Overbeek; Roger W Jelliffe; Johan W Mouton
Population pharmacokinetic analysis of nonlinear behavior of piperacillin during intermittent or continuous infusion in patients with cystic fibrosis.
Antimicrobial agents and chemotherapy 2003;47(2):541-7.
2003: Florent Rougier; michel ducher; Michel Maurin; stephane corvaisier; Daniel Claude; Roger W Jelliffe; Pascal Maire
Aminoglycoside dosages and nephrotoxicity: quantitative relationships.
Clinical pharmacokinetics 2003;42(5):493-500.
2002: Amir Aminimanizani; Paul M Beringer; J Kang; L Tsang; Roger W Jelliffe; Bertrand Shapiro
Distribution and elimination of tobramycin administered in single or multiple daily doses in adult patients with cystic fibrosis.
The Journal of antimicrobial chemotherapy 2002;50(4):553-9.
2002: Roger W Jelliffe
Estimation of creatinine clearance in patients with unstable renal function, without a urine specimen.
American journal of nephrology 2002;22(4):320-4.
2001: M J Montgomery; Paul M Beringer; Amir Aminimanizani; Stan Louie; Bertrand Shapiro; Roger W Jelliffe; Mark A Gill
Population pharmacokinetics and use of Monte Carlo simulation to evaluate currently recommended dosing regimens of ciprofloxacin in adult patients with cystic fibrosis.
Antimicrobial agents and chemotherapy 2001;45(12):3468-73.
2001: Nathalie Bleyzac; Gérard Souillet; P Magron; A Janoly; Patrice Martin; Yves Bertrand; Claire Galambrun; Q Dai; Pascal Maire; Roger W Jelliffe; Gilles Aulagner
Improved clinical outcome of paediatric bone marrow recipients using a test dose and Bayesian pharmacokinetic individualization of busulfan dosage regimens.
Bone marrow transplantation 2001;28(8):743-51.
2001: Nathalie Bleyzac; V Varnier; Jean-Marc Labaune; stephane corvaisier; Pascal Maire; Roger W Jelliffe; G Putet; Gilles Aulagner
Population pharmacokinetics of amikacin at birth and interindividual variability in renal maturation.
European journal of clinical pharmacology 2001;57(6-7):499-504.
2001: Jean-Marc Labaune; Nathalie Bleyzac; Pascal Maire; Roger W Jelliffe; Marie-Jeanne Boutroy; Gilles Aulagner; G Putet
Once-a-day individualized amikacin dosing for suspected infection at birth based on population pharmacokinetic models.
Biology of the neonate 2001;80(2):142-7.
2001: M Milman; F Jiang; Roger W Jelliffe
Creating discrete joint densities from continuous ones: the moment matching-maximum entropy approach.
Computers in biology and medicine 2001;31(3):197-214.
2001: Dominique Breilh; Marie-Claude Saux; Pascal Maire; J M Vergnaud; Roger W Jelliffe
Mixed pharmacokinetic population study and diffusion model to describe ciprofloxacin lung concentrations.
Computers in biology and medicine 2001;31(3):147-55.
2001: Roger W Jelliffe; Pascal Maire
Goal-oriented, model-based drug regimens.
Computers in biology and medicine 2001;31(3):145-6.
2001: michel ducher; Pascal Maire; Catherine Cerutti; Y Bourhis; F Foltz; P Sorensen; Roger W Jelliffe; Jean-Pierre Fauvel
Renal elimination of amikacin and the aging process.
Clinical pharmacokinetics 2001;40(12):947-53.
2001: Amir Aminimanizani; Paul M Beringer; Roger W Jelliffe
Comparative pharmacokinetics and pharmacodynamics of the newer fluoroquinolone antibacterials.
Clinical pharmacokinetics 2001;40(3):169-87.
2000: Roger W Jelliffe; Alan Schumitzky; Michael Van Guilder
Population pharmacokinetics/pharmacodynamics modeling: parametric and nonparametric methods.
Therapeutic drug monitoring 2000;22(3):354-65.
2000: Roger W Jelliffe; David S Bayard; M Milman; Michael Van Guilder; Alan Schumitzky
Achieving target goals most precisely using nonparametric compartmental models and "multiple model" design of dosage regimens.
Therapeutic drug monitoring 2000;22(3):346-53.
2000: Roger W Jelliffe
Goal-oriented, model-based drug regimens: setting individualized goals for each patient.
Therapeutic drug monitoring 2000;22(3):325-9.
2000: Nathalie Bleyzac; B Allard-Latour; A Laffont; J Mouret; Roger W Jelliffe; Pascal Maire
Diurnal changes in the pharmacokinetic behavior of amikacin.
Therapeutic drug monitoring 2000;22(3):307-12.
2000: Paul M Beringer; Alexander Vinks; Roger W Jelliffe; Bertrand Shapiro
Pharmacokinetics of tobramycin in adults with cystic fibrosis: implications for once-daily administration.
Antimicrobial agents and chemotherapy 2000;44(4):809-13.
1998: stephane corvaisier; Pascal Maire; M Y Bouvier d'Yvoire; X Barbaut; Nathalie Bleyzac; Roger W Jelliffe
Comparisons between antimicrobial pharmacodynamic indices and bacterial killing as described by using the Zhi model.
Antimicrobial agents and chemotherapy 1998;42(7):1731-7.
1998: Paul M Beringer; Alexander Vinks; Roger W Jelliffe
Pharmacokinetics of once-daily amikacin dosing in patients with cystic fibrosis.
The Journal of antimicrobial chemotherapy 1998;41(1):142-4.
1998: Roger W Jelliffe; Alan Schumitzky; David S Bayard; M Milman; Michael Van Guilder; X Wang; F Jiang; X Barbaut; Pascal Maire
Model-based, goal-oriented, individualised drug therapy. Linkage of population modelling, new 'multiple model' dosage design, bayesian feedback and individualised target goals.
Clinical pharmacokinetics 1998;34(1):57-77.
1997: Roger W Jelliffe; P Gomis; B Tahani; J Ruskin; Fred R Sattler
A population pharmacokinetic model of trimethoprim in patients with pneumocystis pneumonia, made with parametric and nonparametric methods.
Therapeutic drug monitoring 1997;19(4):450-9.
1996: S Vincent; Pascal Maire; T Bataillard; E Denjean; P Ducrozet; A Laffont; C Visent; Roger W Jelliffe
[Individual variability of pharmacokinetic parameters of amikacin in the elderly: retrospective studies].
Pathologie-biologie 1996;44(7):667-74.
1996: V Bréant; B Charpiat; J M Sab; Pascal Maire; Roger W Jelliffe
How many patients and blood levels are necessary for population pharmacokinetic analysis? A study of a one compartment model applied to cyclosporine.
European journal of clinical pharmacology 1996;51(3-4):283-8.
1995: Pascal Maire; X Barbaut; J C Thalabard; J M Vergnaud; D Roux; M Roy; Roger W Jelliffe
Adaptive control of therapeutic drug regimens relations between clinical situations: outcomes and simulations using nonlinear dynamic models.
Medinfo. MEDINFO 1995;8 Pt 2():1111-5.
1995: Roger W Jelliffe; D Bayard; A Schumitzky; M Milman; M Van Guilder
Pharmaco-informatics: more precise drug therapy from 'multiple model' (MM) adaptive control regimens: evaluation with simulated vancomycin therapy.
Medinfo. MEDINFO 1995;8 Pt 2():1106-10.
1994: Pascal Maire; X Barbaut; J M Vergnaud; M el Brouzi; M A Confesson; C Pivot; M Chuzeville; N Ivanoff; J L Brazier; Roger W Jelliffe
Computation of drug concentrations in endocardial vegetations in patients during antibiotic therapy.
International journal of bio-medical computing 1994;36(1-2):77-85.
1994: Pascal Maire; X Barbaut; P Girard; A Mallet; Roger W Jelliffe; T Berod
Preliminary results of three methods for population pharmacokinetic analysis (NONMEM, NPML, NPEM) of amikacin in geriatric and general medicine patients.
International journal of bio-medical computing 1994;36(1-2):139-41.
1994: Roger W Jelliffe; Pascal Maire; Fred R Sattler; P Gomis; B Tahani
Adaptive control of drug dosage regimens: basic foundations, relevant issues, and clinical examples.
International journal of bio-medical computing 1994;36(1-2):1-23.
1994: B Charpiat; V Breant; C Pivot-Dumarest; Pascal Maire; Roger W Jelliffe
Prediction of future serum concentrations with Bayesian fitted pharmacokinetic models: results with data collected by nurses versus trained pharmacy residents.
Therapeutic drug monitoring 1994;16(2):166-73.
1994: M Grillot; Pascal Maire; M A Confesson; V Cogoluenhes; C Pivot; M Druguet; P Courpron; Roger W Jelliffe
[Adaptive control of therapeutics using amikacin in very old patients: retrospective analysis of efficacy and toxicity].
Pathologie-biologie 1994;42(3):247-53.
1994: M A Confesson; X Barbaut; Pascal Maire; J M Vergnaud; A el Brouzi; Roger W Jelliffe
[Aminoglycoside determinations calculated in endocarditis vegetations. Relations with clinical practices during infectious endocarditis treatment with amikacin].
Thérapie 1994;49(1):27-34.
1994: Roger W Jelliffe; D Bayard; A Schumitzky; M Milman; M Van Guilder
Pharmaco-informatics: more precise drug therapy from "multiple model" (MM) stochastic adaptive control regimens: evaluation with simulated vancomycin therapy.
Proceedings / the ... Annual Symposium on Computer Application [sic] in Medical Care. Symposium on Computer Applications in Medical Care 1994;():972.
1993: Roger W Jelliffe; A Schumitzky; M Van Guilder; M Liu; L Hu; Pascal Maire; P Gomis; X Barbaut; B Tahani
Individualizing drug dosage regimens: roles of population pharmacokinetic and dynamic models, Bayesian fitting, and adaptive control.
Therapeutic drug monitoring 1993;15(5):380-93.
1993: Roger W Jelliffe; B Tahani
Pharmacoinformatics: equations for serum drug assay error patterns; implications for therapeutic drug monitoring and dosage.
Proceedings / the ... Annual Symposium on Computer Application [sic] in Medical Care. Symposium on Computer Applications in Medical Care 1993;():517-21.
1992: P H Maire; X Barbaut; Roger W Jelliffe
Antibiotic dose adjustment in renal insufficiency.
Lancet 1992;340(8833):1478-9; author reply 1480-1.
1991: Roger W Jelliffe; T Iglesias; A K Hurst; K A Foo; J Rodriguez
Individualising gentamicin dosage regimens. A comparative review of selected models, data fitting methods and monitoring strategies.
Clinical pharmacokinetics 1991;21(6):461-78.
1990: A K Hurst; M A Yoshinaga; G H Mitani; K A Foo; Roger W Jelliffe; E C Harrison
Application of a Bayesian method to monitor and adjust vancomycin dosage regimens.
Antimicrobial agents and chemotherapy 1990;34(6):1165-71.
1990: Roger W Jelliffe; A Schumitzky
Modeling, adaptive control, and optimal drug therapy.
Medical progress through technology 1990;16(1-2):95-110.
1987: A K Hurst; K T Iseri; Mark A Gill; J K Noguchi; T M Gilman; Roger W Jelliffe
Comparison of four methods for predicting serum gentamicin concentrations in surgical patients with perforated or gangrenous appendicitis.
Clinical pharmacy 1987;6(3):234-8.